Kentucky legislation · 2026 Regular Session
Kentucky HB512: AN ACT relating to prescription drugs.
Status: In committee, February 4, 2026
Amend KRS 304.17A-164 to define and redefine terms; establish cost-sharing requirements for prescription drugs; require rebates to be passed through; establish confidentiality requirements for the rebate information; create a new section of KRS 365.880 to 365.900 to provide that the actual amount of rebates received is a trade secret; provide that compliance with prescription drug cost-sharing and rebate requirements shall not be in violation of the Uniform Trade Secrets Act; amend KRS 304.17C-125, 304.38A-115, 18A.225, and 164.2871 to apply the cost-sharing and rebate requirements for prescription drugs to limited health service benefit plans, limited health service organizations, the state employee health plan, and self-insured employer group health plans provided by the governing board of a state postsecondary education institution; apply provisions to health plans issued or renewed on or after January 1, 2027; EFFECTIVE January 1, 2027.
What the bill says
An act relating to prescription drugs.
From the introduced text:
AN ACT relating to prescription drugs. Be it enacted by the General Assembly of the Commonwealth of Kentucky: Section 1. KRS 304.17A-164 is amended to read as follows: (1) As used in this section: (a) "Cost sharing": 1. Except as provided in subsection (2) of this section, means the cost to an insured under a health plan according to any coverage limit, copayment, coinsurance, deductible, or other out-of-pocket expense requirements imposed by the plan[, which may be subject to annual limitations on cost sharing, including those imposed under 42 U.S.C. secs. 18022(c) and 300gg-6(b),] in order for the insured to receive a specific health care benefit[service] covered by the plan; and 2. May be subject to annual limitations, including those imposed under 42 U.S.C. secs. 18022(c) and 300gg-6(b); (b) "Generic alternative" means a drug that is designated to be therapeutically equivalent by the United States Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence Evaluations, except that a drug shall not be considered a generic alternative until the drug is nationally available; (c) "Health plan": 1. Means a policy, contract, certificate, or agreement offered or issued by an insurer to provide, deliver, arrange for, pay for, or reimburse any of the cost of health care[ services]; and 2. Includes a health benefit plan; (d) "Insured" means any individual who …
Sponsors
- Kimberly Moser (R, HD-064) · primary sponsor
- Kimberly Banta (R, HD-063)
- Steve Bratcher (R, HD-025)
- Josh Calloway (R, HD-010)
- Stephanie Dietz (R, HD-065)
- Peyton Griffee (R, HD-026)
- Vanessa Grossl (R, HD-088)
- Tony Hampton (R, HD-062)
- Mark Hart (R, HD-078)
- Jason Nemes (R, HD-033)
- Marianne Proctor (R, HD-060)
Latest actions
- : to Banking & Insurance (H)
- : to Committee on Committees (H)
- : introduced in House
Subjects: State Agencies, Education, Higher, Insurance, Health, State Employee Health Plan Mandate, Drugs And Medicines, State Employees, Pharmacists, Local Mandate
Common questions
- What is HB512?
- HB512 is a bill in the Kentucky Legislature (2026 Regular Session): AN ACT relating to prescription drugs.
- What does HB512 do?
- In its own words: An act relating to prescription drugs.
- What is the status of HB512?
- In committee as of February 4, 2026. Latest action: to Banking & Insurance (H) (February 4, 2026).
- Who sponsored HB512?
- Kimberly Moser (R, HD-064), with 10 co-sponsors.
- Where is the official record for HB512?
- On the Kentucky Legislature website: https://apps.legislature.ky.gov/record/26rs/hb512.html
Source: official Kentucky record. Tracked by Delilah, AI for legislation across all 50 states and Congress.